XTNT
XTNT 1-star rating from Upturn Advisory

Xtant Medical Holdings Inc (XTNT)

Xtant Medical Holdings Inc (XTNT) 1-star rating from Upturn Advisory
$0.72
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: XTNT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $1.5

1 Year Target Price $1.5

Analysts Price Target For last 52 week
$1.5 Target price
52w Low $0.34
Current$0.72
52w High $0.95

Analysis of Past Performance

Type Stock
Historic Profit 30.71%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 101.50M USD
Price to earnings Ratio 72.5
1Y Target Price 1.5
Price to earnings Ratio 72.5
1Y Target Price 1.5
Volume (30-day avg) 2
Beta -0.06
52 Weeks Range 0.34 - 0.95
Updated Date 12/14/2025
52 Weeks Range 0.34 - 0.95
Updated Date 12/14/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.01

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 1.32%
Operating Margin (TTM) 7.64%

Management Effectiveness

Return on Assets (TTM) 3.87%
Return on Equity (TTM) 3.64%

Valuation

Trailing PE 72.5
Forward PE -
Enterprise Value 123590074
Price to Sales(TTM) 0.76
Enterprise Value 123590074
Price to Sales(TTM) 0.76
Enterprise Value to Revenue 0.93
Enterprise Value to EBITDA 11.34
Shares Outstanding 140004240
Shares Floating 45275971
Shares Outstanding 140004240
Shares Floating 45275971
Percent Insiders 16.45
Percent Institutions 57.2

About Xtant Medical Holdings Inc

Exchange NYSE MKT
Headquaters Belgrade, MT, United States
IPO Launch date 2015-10-19
President, CEO & Director Mr. Sean E. Browne
Sector Healthcare
Industry Medical Devices
Full time employees 217
Full time employees 217

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.